Featured Research

from universities, journals, and other organizations

Economic analysis: Erlotinib marginally cost-effective

Date:
February 16, 2010
Source:
Journal of the National Cancer Institute
Summary:
Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective.

Weighing both magnitude of survival benefit and expense, researchers found that the drug erlotinib, which was found to improve overall survival by 2 months in patients with advanced non-small cell lung cancer, is marginally cost-effective. The results of their economic analysis using clinical trial data were reported in a new study published online February 16 in the Journal of the National Cancer Institute.

Natasha B. Leighl, M.D., of the University Health Network in Toronto, Canada, and colleagues performed an analysis of erlotinib treatment in the NCIC Clinical Trials Group BR.21 trial to determine the cost-effectiveness of treating various populations with the drug, a tyrosine kinase inhibitor. The researchers also calculated the incremental cost-effectiveness ratio.

The incremental cost-effectiveness ratio for erlotinib treatment in the trial population was $94,638 (2007 Canadian dollar) per life-year gained (95% confidence interval = $52,359 to $429,148).

According to the researchers, this figure exceeds the threshold historically accepted as cost-effective ($50,000 per quality-adjusted life year). The ratio was in the higher range of cost-effectiveness ratios that high-resource countries may consider acceptable. Thus, it may be possible to enhance the cost-effectiveness of this treatment through the clinical and molecular selection of patients for treatment, the authors report.

Subgroup analyses revealed that erlotinib may be more cost-effective in never-smokers or patients with high EGFR gene copy number.

"Ongoing efforts to identify which patients are most likely to benefit from treatment and to make targeted cancer therapies more affordable will serve to make this important treatment option available for lung cancer patients worldwide," the authors write.

In an accompanying editorial, Scott D. Ramsey, M.D., Ph.D., of Fred Hutchinson Cancer Research Center, in Seattle, said the study provided new information to help address some of the questions surrounding the drug's use. Although the study's findings are unlikely to sway any policies, it does provide information on the potential economic impact of biomarker-guided treatment with erlotinib.

"The unwillingness of public and private health systems and providers in the United States to consider costs relative to benefits in decisions about access to these products presents a clear signal to drug manufacturers," he writes. "It also presents the rest of the world with a need for information that identifies patients for whom the amount of benefit of therapies such as erlotinib can support a valid argument for their use."


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Bradbury et al. Economic Analysis: Randomized Placebo-Controlled Clinical Trial of Erlotinib in Advanced Non-Small Cell Lung Cancer. Journal of the National Cancer Institute, 2010; DOI: 10.1093/jnci/djp518

Cite This Page:

Journal of the National Cancer Institute. "Economic analysis: Erlotinib marginally cost-effective." ScienceDaily. ScienceDaily, 16 February 2010. <www.sciencedaily.com/releases/2010/02/100216163334.htm>.
Journal of the National Cancer Institute. (2010, February 16). Economic analysis: Erlotinib marginally cost-effective. ScienceDaily. Retrieved October 2, 2014 from www.sciencedaily.com/releases/2010/02/100216163334.htm
Journal of the National Cancer Institute. "Economic analysis: Erlotinib marginally cost-effective." ScienceDaily. www.sciencedaily.com/releases/2010/02/100216163334.htm (accessed October 2, 2014).

Share This



More Health & Medicine News

Thursday, October 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Might Not Be Out Of Control In U.S., But Coverage Is

Ebola Might Not Be Out Of Control In U.S., But Coverage Is

Newsy (Oct. 2, 2014) Coverage of the lone Ebola patient discovered in Texas has U.S. media in a frenzy — but does the coverage match the reality? Video provided by Newsy
Powered by NewsLook.com
Rhode Island Child With Enterovirus Dies After Infection

Rhode Island Child With Enterovirus Dies After Infection

Reuters - US Online Video (Oct. 2, 2014) A Rhode Island child hospitalized with Enterovirus D68 has died of a bacterial infection, in what state public health officials say was an unusual and dangerous combination. Mana Rabiee reports. Video provided by Reuters
Powered by NewsLook.com
US Hunts Contacts of Ebola Patient, Including Children

US Hunts Contacts of Ebola Patient, Including Children

AFP (Oct. 2, 2014) Health officials in Texas on Wednesday scoured the Dallas area for people, including schoolchildren, who came in contact with a Liberian man who was diagnosed with Ebola in the United States. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Study Says Losing Sense Of Smell Can Indicate Death

Study Says Losing Sense Of Smell Can Indicate Death

Newsy (Oct. 2, 2014) Researchers found elderly adults with a poor sense of smell are more likely to die within five years. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins